ProMIS Neurosciences Files 8-K on Shareholder Vote Matters

TL;DR

ProMIS Neurosciences filed an 8-K on Oct 23rd regarding shareholder votes. Check for details.

AI Summary

ProMIS Neurosciences Inc. filed an 8-K on October 24, 2024, reporting on matters submitted to a vote of security holders as of October 23, 2024. The filing details the company's corporate structure, including its former name Amorfix Life Sciences Ltd. and its incorporation in Ontario, Canada.

Why It Matters

This filing informs shareholders about important corporate actions and decisions that have been or will be put to a vote, impacting their investment and the company's direction.

Risk Assessment

Risk Level: low — This is a routine filing reporting on shareholder votes, not indicating new financial distress or significant operational changes.

Key Numbers

• 001-41429 — SEC File Number (Identifies the company's filing history with the SEC.)

Key Players & Entities

• ProMIS Neurosciences Inc. (company) — Registrant
• October 23, 2024 (date) — Date of earliest event reported
• October 24, 2024 (date) — Date of report
• Amorfix Life Sciences Ltd. (company) — Former company name
• 1920 Yonge Street, Toronto, Ontario M4S 3E2 (address) — Principal executive offices

FAQ

Filing Documents

• pmn-20241023x8k.htm (8-K) — 45KB
• 0001558370-24-013616.txt ( ) — 176KB
• pmn-20241023.xsd (EX-101.SCH) — 4KB
• pmn-20241023_def.xml (EX-101.DEF) — 3KB
• pmn-20241023_lab.xml (EX-101.LAB) — 17KB
• pmn-20241023_pre.xml (EX-101.PRE) — 12KB
• pmn-20241023x8k_htm.xml (XML) — 5KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On October 23, 2024, ProMIS Neurosciences Inc. (the " Company ") held a special meeting of shareholders (the " Special Meeting "). The shareholders considered two proposals, each of which is described in more detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on September 9, 2024. Of the 20,127,783 Common Shares, no par value per share (the " Common Shares "), outstanding as of the record date and eligible for voting, 9,093,432 Common Shares, or approximately 45.17%, were present or represented by proxy at the Special Meeting. Set forth below are the results of the matters submitted for a vote of shareholders at the Special Meeting. Proposal No. 1: To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the potential issuance of the Company's Common Shares underlying the (a) Tranche A Common Share purchase warrants and (b) Tranche B Common Share purchase warrants, each sold in the private placement offering, which closed on July 31, 2024 (the " Stock Issuance Proposal "). Votes For Votes Against Abstained Approve the potential issuance of Common Shares underlying the (a) Tranche A Common Share purchase warrants and (b) Tranche B Common Share purchase warrants, each sold in the private placement offering, which closed on July 31, 2024. 8,948,590 121,116 23,726 Broker Non-Votes: 0 Proposal No. 2: In the event there are not sufficient votes in favor of the foregoing proposal and such proposal is not approved by shareholders, to approve the adjournment of the Special Meeting by the Chairperson to a later date no later than November 22, 2024 at 10:00 a.m., Eastern Time, in accordance with the Company's Bylaws, to solicit additional proxies; provided, the Company shall provide updated instructions to attend such adjournment as necessary (the " Adjourment Proposal "). Although the Adjournment Proposal was deemed not necessary beca

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROMIS NEUROSCIENCES INC. Date: October 24, 2024 By: /s/ Neil Warma Name: Neil Warma Title: Chief Executive Officer